In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: June/July 2008

Executive Summary

June/July 2008 dealmaking highlights: GSK is banking on insomnia with a $560mm pre-commercial value deal for Actelion's Phase III almorexant; Teva expands its hold on worldwide generics through the $8.7bn purchase of Barr; tying PIPEs for the second-most highest biopharma financing type was the Other category, consisting of TPG-Axon's $300mm investment in Lilly to support AD trials; and late VC money dominates medical device financing, accounting for 45% of the $744mm total.



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts